Idelalisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Idelalisib. Educational only — not medical advice.
Labeled uses
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Source: FDA labeling via NIH DailyMed (set efbdafa9…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.